Reply

Affiliations

¹ Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
² Statistics and Data Center, Samsung Medical Center, Seoul, Korea.

Comment

Myung Ji Goh et al. Hepatology. 2020 Jun.

. 2020 Jun;71(6):2174-2175.

doi: 10.1002/hep.31079.

¹ Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
² Statistics and Data Center, Samsung Medical Center, Seoul, Korea.

No abstract available

Comment on

Statin Use and the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B.
Goh MJ, Sinn DH, Kim S, Woo SY, Cho H, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Goh MJ, et al. Hepatology. 2020 Jun;71(6):2023-2032. doi: 10.1002/hep.30973. Epub 2020 Feb 14. Hepatology. 2020. PMID: 31556128
Letter to the Editor: Statins and Reduced Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B.
Huang R, Wang J, Wu W, Yan X, Wu C. Huang R, et al. Hepatology. 2020 Jun;71(6):2173-2174. doi: 10.1002/hep.31080. Hepatology. 2020. PMID: 31858599 No abstract available.

1. Lee TY, Hsu YC, Tseng HC, Yu SH, Lin JT, Wu MS, et al. Association of daily aspirin therapy with risk of hepatocellular carcinoma in patients with chronic hepatitis B. JAMA Intern Med 2019;179:633-640.
1. Lampertico P, Papatheodoridis GV. Is tenofovir superior to entecavir in reducing the risk of hepatocellular carcinoma in chronic hepatitis B? The controversy continues. Gastroenterology 2020;158:42-44.
1. Chang FM, Wang YP, Lang HC, Tsai CF, Hou MC, Lee FY, et al. Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: a population-based study. Hepatology 2017;66:896-907.